Ascaroside Science Eyes a New Delivery Format

Ascribe Bio and Corteva partner to adapt the Phytalix biofungicide for seed treatment against early-season disease

10 Mar 2026

Ascribe Bio and Corteva have launched a multi-year research collaboration to test whether Phytalix, an ascaroside-based biofungicide, can be reformulated as a seed treatment to protect germinating crops against fungal and soil-borne disease.

Phytalix was originally developed for foliar application. It works by activating a plant's own defence mechanisms before disease pressure takes hold, rather than by killing pathogens directly. This mode of action distinguishes it from conventional fungicides and may complement existing disease management programmes. The collaboration aims to extend that mechanism into the germination window, where seedlings face their greatest vulnerability.

Under the agreement, Ascribe Bio will lead laboratory studies and initial field trials. Corteva brings formulation expertise, seed treatment manufacturing capability, and agronomic testing infrastructure across key growing regions.

The partnership builds on an existing financial relationship. Corteva co-invested in Ascribe Bio's $12 million Series A round, closed in October 2025, which funded regulatory preparation and manufacturing scale-up for Phytalix.

Ascarosides are naturally occurring small molecules derived from the soil microbiome, originally isolated through research at Cornell University's Boyce Thompson Institute.

Seed-applied biologicals are among the faster-growing segments of the crop protection market. A single seed treatment application delivers protection at the point of planting, requiring lower input volumes than foliar programmes and integrating readily into existing commercial workflows. For biological technologies, the seed treatment format has become an increasingly attractive target precisely because of that efficiency.

Whether Phytalix's immune-priming mechanism translates effectively to the soil environment, under variable moisture, temperature, and microbial conditions, remains the central question the collaboration must answer. Reformulation for seed compatibility is technically demanding, and field performance at commercial scale is not guaranteed by laboratory results. The outcome will determine whether ascaroside chemistry can compete in one of the biologicals market's most commercially significant segments.